GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Stories, insights,
and updates.

Clinical insights, research updates, and conference highlights in gastroenterology — page 7.

Top Platforms for Publishing Gastroenterology Research in India: A Practical Guide for Clinicians and Researchers (2026)

Top Platforms for Publishing Gastroenterology Research in India: A Practical Guide for Clinicians and Researchers (2026)

You've completed a prospective study on H. pylori eradication failure rates in a tertiary care centre in India. The data is clean, the conclusions are solid, and now you face the question most clinicians skip thinking about until it's too late: where do I publish this? The wrong choice can cost your paper a year in review limbo, bury it behind a paywall your colleagues can't access, or worse - land it in a journal no one reads. This guide cuts through that confusion.

April 22, 2026•GastroAGI Team
Read Now8views
Gut Microbiome Research in India: What the Evidence Shows, What It Doesn't, and What to Do With It Clinically

Gut Microbiome Research in India: What the Evidence Shows, What It Doesn't, and What to Do With It Clinically

A 34-year-old vegetarian woman from Chennai presents with bloating, loose stools, and abdominal cramps for two years. Her colonoscopy is normal. Her H. pylori test is negative. You diagnose IBS-D - but you're treating her with protocols built almost entirely on Western microbiome data, in a patient whose gut flora has almost nothing in common with the cohorts those studies used. That gap is no longer just academic. This post maps what gut microbiome research in India has actually shown, where the critical unknowns remain, and how to use the emerging data in clinical practice today.

April 21, 2026•GastroAGI Team
Read Now9views
NAFLD & MASH Treatment 2026: Resmetirom, Lifestyle & Right Therapy Sequencing

NAFLD & MASH Treatment 2026: Resmetirom, Lifestyle & Right Therapy Sequencing

A 54-year-old woman with type 2 diabetes, BMI 33, and incidentally discovered elevated ALT returns to your clinic. Her FibroScan shows CAP 320 dB/m and liver stiffness of 9.8 kPa. She has tried and abandoned two weight-loss programs. She asks if there is finally a pill for this. For the first time in the 30-year history of NAFLD research, the honest answer is yes - but only if you sequence it correctly.The landscape of NAFLD and NASH treatment has fundamentally shifted since 2023. The nomenclature has moved - the field now formally prefers metabolic-associated steatotic liver disease (MASLD) - but more importantly, the therapeutic toolkit has expanded. Resmetirom received FDA approval in March 2024 as the first drug approved specifically for NASH with liver fibrosis, ending a long drought of failed trials. Simultaneously, GLP-1 receptor agonists have accumulated enough mechanistic and trial data to be used strategically. Despite this, the majority of patients with NAFLD/NASH still arrive in gastroenterology clinics without structured treatment plans - because the decision of who to treat, with what, and when remains genuinely complex. This post provides that framework.

April 20, 2026•GastroAGI Team
Read Now10views
Getting IEC and CDSCO Approval for Gastroenterology Clinical Trials in India: A Step-by-Step Guide

Getting IEC and CDSCO Approval for Gastroenterology Clinical Trials in India: A Step-by-Step Guide

You have a well-designed gastroenterology trial - a prospective cohort comparing fecal microbiota transplantation protocols in recurrent Clostridioides difficile, or a phase II drug trial in refractory IBD. The science is solid. The question everyone asks next is the one nobody teaches in fellowship: How do you actually get this approved in India? This guide walks through the IEC and CDSCO process for gastroenterology clinical trials - what to submit, in what order, and where most investigators lose months they could have saved.

April 16, 2026•GastroAGI Team
Read Now6views
Top Gastroenterology Conferences in India: ISGCON, INASL, SGEI & WCOG 2026

Top Gastroenterology Conferences in India: ISGCON, INASL, SGEI & WCOG 2026

A DM physician at a tier-2 hospital spends hours each week parsing conflicting treatment protocols for NAFLD — one from a US guideline body, another from a European liver society. Neither accounts for Indian dietary patterns, genetic predispositions, or the public-health context of a country carrying nearly 20% of the world's chronic liver disease burden. The answer, most of the time, isn't in a journal — it's on a conference floor in Varanasi, Amritsar, or New Delhi, where Indian gastroenterologists are producing and debating exactly that evidence. This post maps every major national conference where that work happens.

April 15, 2026•GastroAGI Team
Read Now0views
Fatigue in Aging: When to Stop Reassuring and Start Investigating

Fatigue in Aging: When to Stop Reassuring and Start Investigating

Fatigue in older adults is one of the most dismissed symptoms in medicine — and one of the most dangerous to ignore. Nearly one-third of people over 65 report significant fatigue, yet it's routinely chalked up to "just getting older." That assumption costs people years of quality life.Persistent fatigue is a signal, not a sentence. The biological mechanisms driving exhaustion in aging are increasingly well-understood — and many are treatable. Understanding where to draw the line between normal tiredness and a symptom worth pursuing starts at the cellular level.

April 14, 2026•GastroAGI Team
Read Now12views
Why the 6-Month Rule No Longer Holds Up | Early Liver Transplantation for Alcoholic Hepatitis:

Why the 6-Month Rule No Longer Holds Up | Early Liver Transplantation for Alcoholic Hepatitis:

A 34-year-old woman with no prior liver disease presents with her first episode of severe alcoholic hepatitis — Maddrey's Discriminant Function of 68, MELD 28, non-responsive to corticosteroids at day 7. Her family is engaged, she has no prior treatment history, and she is asking the right questions. Your medical options are effectively exhausted. She will likely be dead in weeks. The question is not whether she deserves a transplant. The question is whether a number - six months - should decide that for you.

April 9, 2026•GastroAGI Team
Read Now14views
(2026 Updated) Acute Pancreatitis in 2026: Predicting Severity, Timing Intervention, and Avoiding Common Pitfalls

(2026 Updated) Acute Pancreatitis in 2026: Predicting Severity, Timing Intervention, and Avoiding Common Pitfalls

A 58-year-old woman is admitted with her first episode of acute pancreatitis. Gallstones are the cause. Her initial SIRS criteria are met on two counts, and her creatinine is creeping up. She looks uncomfortable but not critically ill. The question isn't whether she has pancreatitis — it's whether she's about to declare severe disease, whether you should be scanning her now, and whether she'll need a drain or an OR before this admission ends. That decision tree is what this post is built around.

April 7, 2026•GastroAGI Team
Read Now30views
ACLF vs ALF: How to Tell Them Apart and Why It Changes Everything About Treatment

ACLF vs ALF: How to Tell Them Apart and Why It Changes Everything About Treatment

A 58-year-old man with known alcohol-related cirrhosis is admitted with jaundice, confusion, and a bilirubin of 18 mg/dL. Three beds down, a 24-year-old woman with no liver history presents with the same triad — jaundice, encephalopathy, bilirubin of 22 mg/dL — after two weeks of paracetamol overuse. Both patients look critically unwell. Both will be labelled "liver failure" in the initial clerking note. But the diagnosis, prognosis, and management for these two patients are so fundamentally different that conflating them is one of the more consequential errors in hepatology.The distinction between acute-on-chronic liver failure and acute liver failure matters not just academically but at every decision point: who gets admitted to the ICU, who gets listed for transplant, which vasopressors are appropriate, how long you wait before escalating. The challenge is that on a busy admissions ward, the two can look identical for the first few hours. Both present with jaundice, encephalopathy, and coagulopathy. Both can deteriorate within 24 hours. And the underlying liver disease in ACLF may never have been formally diagnosed before. This post is specifically about the diagnostic framework that separates them — and what changes downstream once you get it right.

April 6, 2026•GastroAGI Team
Read Now3views
Previous
167
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer